FMS-like tyrosine kinase 3 (FLT3) mutations represent some of the most pivotal genetic alterations in acute myeloid leukemia (AML), influencing ...

A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

However, these stocks also carry high risk, as their performance is heavily reliant on innovation, clinical trial success, ...

Ventyx Biosciences, Inc.’s VTYX share price has dipped by 5.05%, which has investors questioning if this is right time to buy ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

The oral HER2 inhibitor zongertinib benefited patients with previously treated, HER2-mutated non-small cell lung cancer in a phase I clinical trial, according to results presented by John V. Heymach, ...